Dr. John Ramey, MD
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- University of South Carolina School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 240
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: University of South Carolina School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
SC license 20-27680
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Roper Hospital Charleston, SC
Medical groups
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 240
- Services billed
- 7,879
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, omalizumab, 5 mg | 1,935 | 11 |
| Professional service for preparation and provision of 1 or more antigens | 858 | 31 |
| Test for allergy using allergenic extract | 573 | 16 |
| Professional service for multiple injections of allergen | 380 | 76 |
| Established patient office or other outpatient visit, 30-39 minutes | 155 | 94 |
| Test to measure expiratory airflow and volume | 145 | 70 |
| Professional service for single injection of allergen | 140 | 18 |
| Established patient office or other outpatient visit, 20-29 minutes | 130 | 82 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 103 | 14 |
| Test to measure the level of nitric oxide gas | 96 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in North Charleston, SC | 88 |
| Fluticasone Propionate Other prescribers in North Charleston, SC | 82 |
| Montelukast Sodium Other prescribers in North Charleston, SC | 80 |
| Azelastine Hcl Other prescribers in North Charleston, SC | 64 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in North Charleston, SC | 63 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in North Charleston, SC | 39 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in North Charleston, SC | 31 |
| Dupixent Pen (dupilumab) Other prescribers in North Charleston, SC | 25 |
| Levocetirizine Dihydrochloride Other prescribers in North Charleston, SC | 25 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in North Charleston, SC | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 76 payments worth $6,388 in total to this clinician.
| Consulting Fee | $3,792 |
|---|---|
| Food and Beverage | $2,511 |
| Education | $85.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jun 5, 2025 | Consulting Fee DUPIXENT · Immunology | $2,292 |
| Arcutis Biotherapeutics, Inc. May 6, 2025 | Consulting Fee Zoryve · Dermatology | $1,500 |
| Sanofi-aventis U.S. LLC Sep 3, 2025 | Education DUPIXENT · Immunology · in-kind | $85.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $306,536 in research payments for these studies, mostly to the institutions running them.
- A twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults w…
AstraZeneca Pharmaceuticals LP - A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
Novartis Pharmaceuticals Corporation - Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Genzyme Corporation · Active, not recruiting · NCT05097287 - Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi US Services Inc. · Recruiting · NCT05263206 - A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label…
AstraZeneca Pharmaceuticals LP - A twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults w…
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.